Literature DB >> 24338744

Liver disease is frequently observed in Down syndrome patients with transient abnormal myelopoiesis.

Myoung Ja Park1, Manabu Sotomatsu, Kentaro Ohki, Kokoro Arai, Kenichi Maruyama, Tomio Kobayashi, Akira Nishi, Kiyoko Sameshima, Takeshi Takagi, Yasuhide Hayashi.   

Abstract

Transient abnormal myelopoiesis (TAM) in neonates with Down syndrome (DS) is characterized by the transient appearance of blast cells, which resolves spontaneously. Approximately 20 % of patients with TAM die at an early age due to organ failure, including liver disease. We studied 25 DS-TAM patients retrospectively to clarify the correlation between clinical and laboratory characteristics and liver diseases. Early death (<6 months of age) occurred in four of the 25 patients (16.0 %), and two of those four patients died due to liver failure. Although physiologic jaundice improved gradually after a week, all DS patients had elevated D-Bil levels during the clinical course of TAM, except one who suffered early death. The median peak day of the WBC count, total bilirubin (T-Bil) and D-Bil levels was: day 1 (range day 0-57), day 8 (range day 1-55), and day 17 (range 1-53), respectively. Our results reveal that all patients with DS-TAM may develop liver disease irrespective of the absence or presence of symptoms and risk factors for early death. In patients of DS-TAM, careful observation of the level of D-Bil is needed by at least 1 month of age for the detection of liver disease risk.

Entities:  

Mesh:

Year:  2013        PMID: 24338744     DOI: 10.1007/s12185-013-1487-5

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  32 in total

Review 1.  The management of neoplastic disorders of haematopoiesis in children with Down's syndrome.

Authors:  B Lange
Journal:  Br J Haematol       Date:  2000-09       Impact factor: 6.998

2.  Mongolism and congenital leukemia.

Authors:  G J SCHUNK; W L LEHMAN
Journal:  J Am Med Assoc       Date:  1954-05-15

Review 3.  Transient leukaemia--a benign form of leukaemia in newborn infants with trisomy 21.

Authors:  Alvin Zipursky
Journal:  Br J Haematol       Date:  2003-03       Impact factor: 6.998

4.  Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group Study.

Authors:  Fawaz Al-Kasim; John J Doyle; Gita V Massey; Howard J Weinstein; Alvin Zipursky
Journal:  J Pediatr Hematol Oncol       Date:  2002-01       Impact factor: 1.289

5.  High expression of platelet-derived growth factor and transforming growth factor-beta 1 in blast cells from patients with Down Syndrome suffering from transient myeloproliferative disorder and organ fibrosis.

Authors:  H Hattori; A Matsuzaki; A Suminoe; K Ihara; H Nakayama; T Hara
Journal:  Br J Haematol       Date:  2001-11       Impact factor: 6.998

Review 6.  Conjugated hyperbilirubinemia in children.

Authors:  David Brumbaugh; Cara Mack
Journal:  Pediatr Rev       Date:  2012-07

Review 7.  Down syndrome, transient myeloproliferative disorder, and infantile liver fibrosis.

Authors:  M Schwab; C Niemeyer; U Schwarzer
Journal:  Med Pediatr Oncol       Date:  1998-09

8.  Guideline for the evaluation of cholestatic jaundice in infants: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition.

Authors:  Virginia Moyer; Deborah K Freese; Peter F Whitington; Alan D Olson; Fred Brewer; Richard B Colletti; Melvin B Heyman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2004-08       Impact factor: 2.839

9.  A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481.

Authors:  Gita V Massey; Alvin Zipursky; Myron N Chang; John J Doyle; Suhail Nasim; Jeffrey W Taub; Yaddanapudi Ravindranath; Gary Dahl; Howard J Weinstein
Journal:  Blood       Date:  2006-02-09       Impact factor: 22.113

10.  Demographic study of leukaemia presenting within the first 3 months of life in the Northern Health Region of England.

Authors:  R P S Bajwa; R Skinner; K P Windebank; M M Reid
Journal:  J Clin Pathol       Date:  2004-02       Impact factor: 3.411

View more
  4 in total

1.  Role of monocyte chemoattractant protein-1 in liver fibrosis with transient myeloproliferative disorder in down syndrome.

Authors:  Kenichiro Kobayashi; Takako Yoshioka; Jun Miyauchi; Atsuko Nakazawa; Nobutaka Kiyokawa; Toshiro Maihara; Ikuya Usami
Journal:  Hepatol Commun       Date:  2018-02-01

2.  Altered pro-inflammatory and anti-inflammatory plasma cytokines levels in children with Down's syndrome: A meta-analysis.

Authors:  Nitu Nigam; Prithvi K Singh; Neena Raizada; Balendra P Singh; Shalini Tripathi; Monica Agrawal; Harish Gupta; Sharad Singh; Ghizal Fatima; Sanjay K Nigam; Shailendra K Saxena
Journal:  J Family Med Prim Care       Date:  2021-11-05

Review 3.  Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update.

Authors:  Neha Bhatnagar; Laure Nizery; Oliver Tunstall; Paresh Vyas; Irene Roberts
Journal:  Curr Hematol Malig Rep       Date:  2016-10       Impact factor: 3.952

4.  Transient Abnormal Myelopoiesis: A Varied Spectrum of Clinical Presentation.

Authors:  Amitabh Singh; Anirban Mandal; Vijay Guru; Sindhu Srinivasan; Rachna Seth
Journal:  J Hematol (Brossard)       Date:  2017-03-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.